What Are HRR Genes and How Do They Impact Cancer Care?

HRR genes are a family of genes whose proteins work together to fix one of the most dangerous types of DNA damage a cell can experience: a complete break across both strands of the double helix. When these genes function normally, they orchestrate a precise repair process called homologous recombination, using a sister copy of the chromosome as a template to restore the broken DNA without errors. When they are mutated or missing, cells lose access to this high-fidelity repair system and become prone to accumulating genetic mistakes, which is why HRR gene mutations are so tightly linked to cancer risk and, paradoxically, to certain cancer treatment strategies.

What Double-Strand Breaks Are and Why They Matter

Your DNA suffers thousands of small injuries every day from normal metabolism, sunlight, and environmental chemicals. Most of these are single-strand nicks or base modifications that the cell patches up routinely. A double-strand break is different: both rails of the DNA ladder snap at roughly the same spot. Left unrepaired, this can lead to chromosome fragmentation and cell death; repaired sloppily, it can shuffle or delete chunks of genetic information and push a cell toward cancer.

Cells have two main strategies for dealing with double-strand breaks. The faster option, called non-homologous end joining (NHEJ), essentially glues the broken ends back together without checking a template. It works in about half an hour, but it often introduces small insertions or deletions at the repair site because the ends get chewed back before ligation.

¹ The second option is homologous recombination repair, which takes considerably longer, around seven hours or more in human cells, but produces an essentially error-free result because it copies the missing information from an intact sister chromatid.² The genes that carry out this second strategy are the HRR genes.

How Homologous Recombination Repair Works

When a double-strand break occurs and a sister chromatid is available as a template, a cascade of HRR proteins springs into action. The process begins with the broken ends being trimmed back to expose single-stranded DNA tails. These tails then invade the intact sister chromatid, searching for a matching sequence. Once a match is found, the cell’s replication machinery uses the undamaged strand as a blueprint to synthesize new DNA across the gap, and the chromosomes are ultimately separated and restored to their original state.³

Because homologous recombination needs a sister chromatid to copy from, it is most active during and just after DNA replication (the S phase of the cell cycle), when a duplicate copy of each chromosome is physically present. NHEJ, by contrast, operates throughout the cell cycle and remains the dominant repair pathway even in phases where HR is available.⁴ This means that HR is not the cell’s go-to for every break. It is the high-fidelity backup that prevents the kind of genomic instability that accumulates over a lifetime and drives cancer.

The Key HRR Genes

When researchers or oncologists refer to “HRR genes,” they typically mean a panel of roughly a dozen to two dozen genes. The most widely recognized are BRCA1, BRCA2, ATM, PALB2, CHEK2, RAD51 and its paralogs (RAD51B, RAD51C, RAD51D), BRIP1, BARD1, FANCL, CDK12, and NBN, among others. Each plays a distinct role in the repair process, but many of them work in concert.

BRCA1 and BRCA2 are the best known because inherited mutations in either gene dramatically raise the lifetime risk of breast and ovarian cancer. But the two proteins do quite different things during repair. BRCA1 acts early, helping the cell recognize the break and commit to using homologous recombination rather than the faster, sloppier NHEJ. BRCA2 acts later, loading the RAD51 protein onto the exposed single-stranded DNA so it can carry out the actual strand invasion of the sister chromatid. The bridge between these two steps is PALB2, which physically links BRCA1 to BRCA2. When the BRCA1–PALB2 connection is disrupted, BRCA2 and RAD51 cannot get to the break site, and recombination fails.⁵⁶

ATM and CHEK2 sit even further upstream, acting as damage sensors. ATM detects the break and sends a signal that activates BRCA1 and other downstream repair proteins. CHEK2 works as a checkpoint kinase, pausing the cell cycle to give the repair machinery time to act. Mutations in any of these genes leave a gap in the repair relay, and the downstream consequences are similar: the cell becomes dependent on error-prone repair, accumulates mutations faster, and is more likely to become cancerous.

How Common Are HRR Mutations in Cancer?

The frequency of HRR gene alterations varies by tumor type, but a consistent theme across studies is that they show up in a meaningful fraction of many common cancers. In ovarian cancer, one study found that about 71% of patients carried mutations in at least one of 14 tested HRR genes, with BRCA2 being the most frequently altered, followed by BRCA1 and ATM.⁷ In a Taiwanese breast cancer cohort, about a quarter of tumors harbored at least one HRR gene mutation, with BRCA1 and BRCA2 collectively altered in roughly 6% and non-BRCA genes like ARID1A, PALB2, and PTEN making up most of the rest.⁸

In prostate cancer, HRR mutations are found in up to about a quarter of patients with metastatic castration-resistant disease.⁹ One Chinese prostate cancer study detected somatic HRR mutations in about 3% and germline HRR mutations in about 4% of patients, with BRCA2 and ATM leading both categories.¹⁰ Pancreatic ductal adenocarcinoma shows HRR alterations in roughly 12% of cases.¹¹

An important distinction runs through these numbers: mutations can be germline (inherited and present in every cell of the body) or somatic (arising only in the tumor itself). Germline mutations carry implications for family members and cancer screening, while somatic mutations matter mainly for treatment decisions. Interestingly, germline HRR mutations appear to produce a stronger “homologous recombination deficiency” signature in tumors than somatic ones. In one study of non-BRCA HRR gene mutations, about half of patients with germline changes showed an HRD-positive score, compared with roughly a fifth of those with somatic-only changes.¹²

Why HRR Mutations Change How Cancers Respond to Treatment

Here is where the biology gets genuinely useful for patients. Cells that have lost their ability to perform homologous recombination are forced to rely entirely on NHEJ and other backup repair pathways to survive DNA damage. Platinum-based chemotherapy drugs (like cisplatin, carboplatin, and oxaliplatin) work partly by creating DNA crosslinks that, when they stall a replication fork, generate double-strand breaks. Cells with functional HR can repair those breaks cleanly. Cells without it cannot, and they die. This is why tumors carrying HRR mutations often respond unusually well to platinum chemotherapy.

In pancreatic cancer, patients with inactivating HRR mutations who received oxaliplatin-based chemotherapy had a median time before their disease progressed of nearly 21 months, compared with under 2 months for patients without such mutations.¹³ A separate analysis of over 2,300 pancreatic cancer patients found that those with HRR-altered tumors had significantly longer overall survival than those with intact HRR.¹⁴ Similar patterns show up in non-small cell lung cancer, where patients with DNA damage repair mutations showed improved survival on platinum-based regimens compared to those without.¹⁵

The same vulnerability is exploited by PARP inhibitors (drugs like olaparib, niraparib, rucaparib, and talazoparib). PARP enzymes normally help repair single-strand DNA breaks. When you block them, single-strand breaks pile up and eventually become double-strand breaks during replication. A normal cell handles those with homologous recombination and carries on. An HRR-deficient cancer cell cannot, and the unrepaired breaks accumulate until the cell dies. This concept, called synthetic lethality, is the principle behind using PARP inhibitors specifically in tumors with BRCA or other HRR gene mutations.

In ovarian cancer, patients with HRR pathway mutations had a median progression-free survival of 36 months, compared with roughly 14 months for those without.¹⁶ Clonal HRR mutations (those present in all tumor cells, not just a subpopulation) were especially strongly linked to better outcomes on platinum chemotherapy, whereas subclonal HRR mutations showed no such benefit.¹⁷ That distinction matters clinically: not all HRR mutations are created equal in terms of treatment response.

BRCA Versus Non-BRCA HRR Mutations

While BRCA1 and BRCA2 get most of the attention, the broader family of HRR genes is increasingly shaping treatment decisions. In metastatic castration-resistant prostate cancer, patients with BRCA mutations had the worst overall survival, but patients with non-BRCA HRR mutations (in genes like ATM, PALB2, or CHEK2) also fared significantly worse than those with no HRR mutations at all.¹⁸ The clinical response to PARP inhibitors is generally strongest for BRCA-mutated tumors, but some patients with other HRR gene mutations also benefit, which is why current testing panels look well beyond BRCA1 and BRCA2.

In high-risk breast cancer patients, one study found that about 22% carried germline mutations (most in BRCA1/2 but a few in other HRR genes) and 9% had somatic-only mutations. The somatic mutations tended to cluster in non-BRCA genes and were linked to more aggressive features like lymphovascular invasion and distant spread.¹⁹ These findings are part of the push toward broader genomic profiling for all patients with advanced or high-risk cancers, not just those with a family history suggesting BRCA involvement.

How Tumors Develop Resistance

One of the frustrating realities of treating HRR-mutated cancers is that many eventually find a way around the vulnerability. The most well-documented escape route is called a reversion mutation. The original mutation that disabled, say, BRCA2 might be a small deletion that disrupted the gene’s reading frame and stopped it from producing a functional protein. Under the selective pressure of PARP inhibitor or platinum therapy, a second mutation can arise in the same gene that restores the reading frame, allowing functional BRCA2 protein to be made again. Once homologous recombination is back online, the tumor is no longer trapped by the synthetic lethality that made the drug work in the first place.²⁰

Reversion mutations have been documented across cancer types. A large pan-cancer analysis of over 650 patients with germline HRR mutations found reversion mutations in about 1.7%, primarily in patients with breast, ovarian, pancreatic, and lung cancers.²¹ Reversions have been identified not just in BRCA1 and BRCA2 but also in PALB2 and RAD51D, and they tend to emerge after platinum or olaparib treatment.²² Detecting these reversions early through blood-based tumor DNA testing is an active area of research, because catching them could prompt a switch to a different treatment strategy before resistance becomes clinically apparent.

Combining PARP Inhibitors with Immunotherapy

A newer frontier in treating HRR-mutated cancers involves pairing PARP inhibitors with immune checkpoint inhibitors. The reasoning is straightforward: HRR-deficient tumors accumulate a heavier burden of mutations and genomic instability. This produces more abnormal proteins that the immune system can recognize as foreign, potentially making these tumors more visible to immune attack. PARP inhibitors, by amplifying DNA damage further, may increase this immune visibility even more.²³

The combination is being explored in several cancers, with ovarian cancer at the leading edge of clinical trials.²⁴ Results so far are mixed but promising enough to keep the approach moving forward. The hope is that the two drug classes attack the tumor from different angles: the PARP inhibitor exploits the DNA repair defect directly, while the immune checkpoint inhibitor unleashes the patient’s own immune cells against the increasingly unstable cancer cells.

Inducing HRR Deficiency in Tumors That Do Not Have It Naturally

The obvious limitation of synthetic lethality is that it works only in the subset of tumors with HRR mutations. Researchers are now investigating whether they can artificially disable homologous recombination in tumors that have intact HRR genes, effectively manufacturing the vulnerability. One approach uses drugs that inhibit ATR, CHK1, or WEE1, proteins involved in the DNA damage response and cell cycle checkpoints. Lab data shows these inhibitors can create an HRR-deficient state in otherwise HR-competent cells, sensitizing them to PARP inhibitors through what has been called “induced synthetic lethality.”²⁵

In bladder cancer, targeting ATR has been proposed as a dual strategy: direct ATR inhibition sensitizes tumors to radiation, while the compensatory upregulation of RAD51-mediated repair that follows creates a new targetable dependency.²⁶ These strategies are still largely preclinical, but they represent a conceptual shift: rather than waiting for nature to hand you a tumor with an HRR defect, you create the defect pharmacologically and then exploit it.

HRR Genes Beyond Cancer

While cancer dominates the clinical conversation around HRR genes, defects in this pathway show up in other medical contexts. Fanconi anemia, a rare inherited condition that causes bone marrow failure, developmental abnormalities, and a high risk of certain blood cancers, is caused by mutations in the Fanconi anemia pathway, which overlaps extensively with homologous recombination. Several established HRR genes, including BRCA2 (also called FANCD1), PALB2 (FANCN), and RAD51C (FANCO), double as Fanconi anemia complementation genes. Patients with biallelic mutations in these genes (meaning both copies are broken) develop the full Fanconi anemia syndrome, whereas those with one working copy typically present with cancer predisposition without the bone marrow failure.²⁷

Environmental Stressors That Tax the HRR System

The HRR pathway does not exist in a vacuum. Everyday chemicals can put extra strain on it, and that strain matters more if you are already carrying one mutated copy of a key gene. Research published in Cell showed that formaldehyde, a compound produced naturally by human metabolism and found widely in the environment, can destabilize DNA replication forks and selectively deplete BRCA2 protein through proteasomal degradation. In cells carrying just one functional copy of BRCA2 (the situation of most BRCA2 mutation carriers, who inherit one broken copy and one working copy), even brief exposure to natural concentrations of formaldehyde was enough to tip the cell into a functionally BRCA2-deficient state, triggering chromosome abnormalities. Acetaldehyde, a byproduct of alcohol metabolism, produced similar effects.²⁸

The implication is thought-provoking: for someone who carries a heterozygous BRCA2 mutation, common environmental exposures may periodically knock their remaining BRCA2 below the threshold needed for effective repair, creating windows of genomic vulnerability. This adds a metabolic and environmental dimension to what is usually framed as purely a genetic risk, and it raises questions about whether lifestyle factors like alcohol consumption could modulate cancer risk in BRCA mutation carriers through this mechanism. The research on this front is still young, but it suggests that carrying a single mutant copy of an HRR gene is not a fixed state of partial protection; it is a balance that environmental factors can tip.